Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Two expert thoracic oncologists discuss novel anti-TIGIT immunotherapies for treatment of NSCLC, from Clinical Care Options (CCO)

Ani Balmanoukian, MD Jyoti D. Patel, MD Released: May 3, 2022

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of TIGIT and emerging therapies for targeting TIGIT, including current trial data, from Clinical Care Options (CCO)

Diwakar Davar, MD Jyoti D. Patel, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 27, 2022 Expired: April 26, 2023

Diwakar Davar, MD, and Jyoti D. Patel, MD, review the role of TIGIT and investigational therapies being evaluated in solid tumors, from Clinical Care Options (CCO)

Diwakar Davar, MD Jyoti D. Patel, MD Released: April 27, 2022